Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jan 18;79(2):163-168.
doi: 10.1136/thorax-2022-218670.

Prospective study of e-cigarette use and respiratory symptoms in adolescents and young adults

Affiliations

Prospective study of e-cigarette use and respiratory symptoms in adolescents and young adults

Alayna P Tackett et al. Thorax. .

Abstract

Rationale: Electronic cigarette (e-cigarette) aerosol contains volatile aldehydes, including flavourings and oxidant metals with known pulmonary toxicity.

Objectives: To evaluate the associations of e-cigarette use with symptoms of wheeze, bronchitic symptoms and shortness of breath (SOB) across 4 years of prospective data.

Methods: Participants completed questionnaires on respiratory symptoms and past 30-day e-cigarette, cigarette and cannabis use in 2014 (wave 1; N=2094; mean age 17.3 years, SD=0.6 years). Follow-up information was collected in 2015 (wave 2; n=1609), 2017 (wave 3; n=1502) and 2018 (wave 4; n=1637) using online surveys. Mixed-effects logistic regression models evaluated associations of e-cigarette use with respiratory symptoms.

Measurements and main results: Participants were mostly Hispanic white (51.8%) and evenly representative by sex (49.6% female; 50.4% male). Compared with never e-cigarette users, past 30-day e-cigarette users reported increased odds of wheeze (OR 1.81; 95% CI 1.28, 2.56), bronchitic symptoms (OR 2.06; 95% CI 1.58, 2.69) and SOB (OR 1.78; 95% CI 1.23, 2.57), adjusting for study wave, age, sex, race, lifetime asthma diagnosis and parental education. Effect estimates were attenuated (wheeze (OR 1.41; 95% CI 0.99, 2.01), bronchitic symptoms (OR 1.55; 95% CI 1.18, 2.05), SOB (OR 1.48; 95% CI 1.01, 2.18)), after adjusting additionally for current cigarette use, cannabis use and secondhand exposure to e-cigarettes/cigarettes/cannabis.

Conclusions: E-cigarette use in young adults was associated with respiratory symptoms, independent of combustible cannabis and cigarette exposures.

Keywords: Tobacco and the lung.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1.
Figure 1.
Prevalence of current respiratory symptoms (wheeze, shortness of breath, and bronchitic symptoms) among study participants across each wave.
Figure 2.
Figure 2.
Prevalence of current e-cigarette, cigarette, and cannabis use among study participants across each wave.

References

    1. Wang TW, Gentzke A, Sharapova S, Cullen KA, Ambrose BK, Jamal A. Tobacco product use among middle and high school students—United States, 2011–2017. Morbidity and Mortality Weekly Report. 2018;67(22):629. - PMC - PubMed
    1. Choi BM, Abraham I. The Decline in e-Cigarette Use Among Youth in the United States—An Encouraging Trend but an Ongoing Public Health Challenge. JAMA Network Open. 2021;4(6):e2112464-e. - PubMed
    1. Cooper M Notes from the field: E-cigarette use among middle and high school students—United States, 2022. MMWR Morbidity and Mortality Weekly Report. 2022;71. - PMC - PubMed
    1. Allen JG, Flanigan SS, LeBlanc M, Vallarino J, MacNaughton P, Stewart JH, et al. Flavoring chemicals in e-cigarettes: diacetyl, 2, 3-pentanedione, and acetoin in a sample of 51 products, including fruit-, candy-, and cocktail-flavored e-cigarettes. Environmental health perspectives. 2016;124(6):733–9. - PMC - PubMed
    1. Lee MS, LeBouf RF, Son YS, Koutrakis P, Christiani DC. Nicotine, aerosol particles, carbonyls and volatile organic compounds in tobacco- and menthol-flavored e-cigarettes. Environ Health. 2017;16(1):42. Epub 2017/04/30. doi: 10.1186/s12940-017-0249-x. PubMed PMID: 28449666; PubMed Central PMCID: PMCPMC5406907. - DOI - PMC - PubMed

LinkOut - more resources